Fulgent Genetics, Inc. 8-K

What Happened

• On May 21, 2026, Fulgent Genetics, Inc. announced that an abstract titled “FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), Abstract #6020” was released, presenting interim data from the company’s open‑label, randomized Phase 2 study. The announcement was made via a press release, which the company filed as Exhibit 99.1 to its Form 8‑K.

Key Details

• Date of announcement: May 21, 2026.
• Study: open‑label, randomized Phase 2 trial of FID‑007 in combination with cetuximab for recurrent or metastatic HNSCC.
• Abstract ID: #6020.
• Disclosure: interim data were presented and summarized in the company’s press release (filed with the 8‑K).

Why It Matters

• This filing signals a clinical development milestone for Fulgent’s FID‑007 program by publicly releasing interim Phase 2 data, which investors can review to assess trial progress. The press release provides the first formal market disclosure of these interim results and the study context (combination with cetuximab in R/M HNSCC).